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Protein–protein interactions (PPIs) play a critical role in many essential biological processes, and numerous
diseases result from malfunctioning PPIs. The modulation of undesirable PPIs via synthetic chemical
molecules has long been considered of medical importance, but still remains challenging. Thanks to the
development of synthetic chemistry, chemists can synthesize protein/peptide secondary structure
mimics to modulate the speciﬁc PPIs. This review discusses general aspects of novel artiﬁcial peptide
secondary structure mimics for the modulation of PPIs, their therapeutic applications and future prospects.1. Introduction
Biological systems are highly complicated and regulated by
sophisticated protein–protein interactions (PPIs).1 Almost all
important biological processes, such as cellular signaling
cascades or the infection of viruses, are closely related to PPIs.2,3
The malfunction of PPIs may be the cause of notorious
diseases.4 Potent small molecule therapeutics have been
developed for targeting PPIs in recent decades.5 However, the
disruption of PPIs by small molecule binders continues to be
diﬃcult to achieve,6–8 because these interactions always involve
relatively large binding areas,9,10 i.e., the interface area between
a protein signaling molecule and its receptor can range to
thousands of A˚2 (Fig. 1).11,12ion between human programmed
ith an interaction area of 1970 A˚2.16
and Technology of China, Hefei 230026,
, Beijing 100084, China
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ia Institute of Technology, Pasadena,
hemistry 2016With the increasing number of protein structure–activity
relationship studies, we have gradually gained a better under-
standing of PPIs. The binding aﬃnity between two proteins de
facto comes from several key residues named “hotspot” or
“anchor” residues,13 and the 20 natural amino acids have
diﬀerent contributions to these vital sites.14 Although these
localized secondary motifs, known as “epitopes”,15 are neces-
sary for recognition, they may simply provide a scaﬀold to
support these hotspots and mediate the interactions between
two huge proteins. Thus, an alternative strategy is to generate
articially designed molecules to provide a similar scaﬀold to
support the hotspots.
Native proteins can theoritically be directly used to inhibit
PPIs. However, typical half-lives of proteins in living cells are
just hours (with a mean half-life of 43 min).17 Moreover, using
entire proteins directly as pharmaceuticals requires suitable
potency and pharmacokinetic properties.18 But to date our
ability to produce homogeneous proteins, especially those with
posttranslational modications, have been limited.19–22 Exam-
ples of monoclonal antibodies performing as antitumor drugs
do exist, such as Bevacizumab,23 Nivolumab and Ipilimumab.24
However, the immune eﬀects and safety prole over the long
term are still concerns. Truncated proteins, or simply peptides
with protein secondary structures, could provide potential
solutions. Based on this concept, rational design based on X-ray
crystallography and theoretical calculations,25 and random
peptide screening such as phage display26 are combined in
search of the minimal or simplied peptide segment that is
required.27 However, these separated peptides tend to act
diﬀerently compared with their behaviour in whole proteins,
because the enthalpy change of secondary interactions in
a limited region might not be enough to compensate for the
entropy loss during the folding process.28
To retain the shape of the a-helix, some additional covalent
bonds are needed. One practical strategy to stabilize a-helixRSC Adv., 2016, 6, 61599–61609 | 61599
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View Article Onlinepeptides was introduced by Verdine and collaborators,29 and
a large variety of chemical bonds and structures have subse-
quently been utilized to achieve this goal in these conforma-
tionally locked peptides, which are descriptively named stapled
peptides. With staples using “native” disulde bonds,30 all-
hydrocarbon cross-links,31 hydrocarbon chains,32 ring closing
metathesis reaction (RCM) linkage,33 Cu(I) catalyzed azide/
alkyne cycloaddition (CuAAC) based linkage,34 or dia-
minodiacid building block linkage,35,36 such peptides show
bioactivity comparable with the native binding moiety37 even
under in vivo conditions.38 This method largely equips us with
the capability to handle helices for further analysis, stimulation
and inhibition,39,40 and also provides a powerful weapon for
current drug design.41
However, it is still diﬃcult to stabilize other secondary
structures (strands, turns, loops) besides a-helices. Those
bioactive conformations mediate most biological processes that
dene growth, ageing, disease and death. For example, isolated
b-strands have a high tendency for aggregation, which is the
major factor causing neurodegenerative diseases such as Alz-
heimer’s disease.42 Additionally, the delivery of both proteins
and peptides can be problematic unless specially facilitated,43
especially when treated as oral drugs.44 To summarize, people
have started to look for other alternatives with high compara-
bility and better performance compared with the skeletons
coming from native proteins to overcome these challenges.
In this review, we will focus on summarizing the existing
molecular designs of protein and peptide secondary structure
mimics. “Peptide secondary structure mimics” will be used to
indicate a more specic structural mimicking purpose, instead
of the term “peptidomimetics”. These designs are generally
targeting a structural similarity to the a-helix, b-strand/b-sheet/
b-hairpin,45 and various turns based on numerous physical
chemistry principles (Fig. 2). Some of these diverse and
sophisticated structures have already been used as PPI inhibi-
tors for a number of therapeutic purposes. Furthermore,
mimetics have also demonstrated the importance of chemical
design in the process of modifying and changing the nature of
proteins and peptides. We will divide them into three main
categories based on their chemical structure designs. TheFig. 2 Three secondary structures of Tobacco Etch Virus (TEV)
protease C151A mutant. PDB ID: 1Q31. a-Helix range from E24-T29:
orange; b-turn range from G53-V66: dark blue; b-sheets range from
N185–N192: light blue.
61600 | RSC Adv., 2016, 6, 61599–61609synthesis processes, structural analysis, and some applications
will also be introduced.2. a-Peptides with non-native amino
acid units to modulate protein–protein
interactions
Non-native amino acid containing a-peptides have been widely
used for the modulation of protein–protein interactions. This
kind of secondary structure mimic is usually generated by the
introduction of non-native amino acid units into native
peptides/proteins by peptide/protein total synthesis,46–49 semi-
synthesis,50–53 or noncanonical amino acid incorporation tech-
nique (ncAA)54,55 combined with bioorthogonal reactions.56,57
Therefore, the development of new synthetic strategies is always
of potential advantage for the preparation of novel
structures.58–612.1 Non-native amino acid units mimicking turn structures
The introduction of non-peptidic units into a native peptide
chain is mostly applied as turn-mimics. Turns reverse the
direction of peptide helices and strands to form compact
structures. They serve as epitopes in peptides and proteins.
Both cyclic structures and acyclic structures have been exploited
to mimic turns, with conformational constraint as the key
requirement.62
2.1.1 Cyclic structure units. Cyclic units have been utilized
to mimic turn structures since the 1980s.63 Kelly’s group64 re-
ported the nucleation of anti-parallel b-sheets in water by har-
nessing a dibenzofuran unit, which formed a turn structure by
folding against the sheet and generating a hydrophobic cluster
with the side chains of the neighbouring residues (Fig. 3a).
Nowick’s group65 developed a more simplied approach to
mimic a hairpin turn structure in chloroform, with a hybrid
oligomer (oligourea and azapeptide) containing peptide
(Fig. 3b). The turn-like structures generated in this way con-
tained two intramolecular hydrogen bonds. Additionally,Fig. 3 Cyclic structure units serving as turn mimics. (a) Dibenzofuran
derivative, (b) oligourea and azapeptide derivative, (c) azacycloalkane
and azabicycloalkane amino acid derivatives (n ¼ 0, 1 or 2, X ¼ C or S),
(d) furanoid sugar amino acid derivative, (e) bicyclo[2.2.1]heptane
derivatives, (f) simple alkane chain derivatives.
This journal is © The Royal Society of Chemistry 2016
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View Article OnlineLubell’s group66 designed, synthesized, and analysed a series of
azacycloalkane and azabicycloalkane amino acid derivatives as
constrained peptide analogues (Fig. 3c) and their derivatives.67 In
model peptide systems, they showed that these tools could be
used to mimic the dihedral angles in the backbones of type II b-
turn, type VI b-turn and g-turn. The same group68 also applied
several azacycloalkane containing turnmimics to the study of the
structure–activity relationship in the interaction between the
opioid receptor-like (ORL1) receptor and its peptide ligands. The
result suggested two new antagonists, mimicking the central
position of i + 1 and i + 2 of the typical Viab-turn, exhibited higher
selectivity over m-and k-opioid receptors (hMOR and hKOR).
Even sugar amino acids can be applied for the generation of
turn structures. Grotenbreg69 et al. created an unusual reverse
turn structure with a furanoid sugar containing amino acid, and
this novel turn structure was used to replace the native turn unit
in the antibiotic gramicidin S (Fig. 3d). Structural analysis
showed the entire secondary structure was supported by the
unexpected turn of the non-natural unit, which could improve
the pharmaceutical properties of cyclic peptides as an antibac-
terial drug.70,71 It is noteworthy that some rationally designed
external units might not form structures as expected. Ranga-
nathan et al.72 and Jones et al.73 designed bicyclo[2.2.1]heptane
derivatives as proline structure mimics to provide nucleating
turn mimics, separately (Fig. 3e). However, the crystal structure
exhibited a diﬀerent folding model for this group of oligomer.
An increasing number of novel turn mimics are being devel-
oped with a more specic purpose of targeting, such as
benzazepin-3-one or benzodiazepinone derivatives as a new
group of b-turn74 or g-turn mimics,75 respectively. More
complicated motifs with turn structures as a b-hairpin motif
have also been mimicked76 and characterized.77
2.1.2 Acyclic structure units. Besides those cyclic units,
simple alkane chains (such as long chain u-amino acids) have
been used to replace those complex structures. This idea was
rst realized by the Nowick group,78 and the characterizations
showed an expected turn structure (Fig. 3f). Furthermore, the
Gellman group79 reported an acyclic b-turn mimic utilizing
alkene structures that could mimic amide bonds in natural
turns. The acyclic structure, trans-5-amino-3,4-dimethylpent-3-
enoate residue, could avoid the allylic strain in the trans-
alkene moiety and promote the backbone to adopt b-turn and b-
hairpin conformations. These acyclic turn mimics have theo-
retically fullled the purpose of mimic generation on the design
level, and they were on the way to being widely applied to more
specic PPI target inhibitions.80Fig. 4 Non-native amino acid units used to mimic other localized
structures: (a) cis,trans-peptide bond, and (b) amide bond isosteres, (c)
triﬂuoromethylated(E)-alkene isostere as a peptide bond mimic, (d)
oxetanylamine structure as a peptide bond mimic.2.2 Non-native amino acid units used to mimic other
localized structures
Non-native structures can also be incorporated into peptides to
endow peptides with certain natural or non-natural structures
and properties.81,82 For example, non-natural units can mimic
a cis peptide bond, which normally requires a proline in natural
peptides. The ability to control the cis/trans geometry of peptide
bonds is also important for the synthesis of turn mimics.This journal is © The Royal Society of Chemistry 20161,2,3-Triazoles, easily generated by Huisgen cycloaddition
reactions, can be good peptide bondmimics.83 Methods have been
developed for the synthesis of 1,2,3-triazoles using copper-catalyzed
azide alkyne cycloaddition84 (CuAAC)85 or ruthenium-catalyzed
azide alkyne cycloaddition86,87 (RuAAC). The products have
similar structures and electronic properties to those of peptide
bonds. Ghadiri’s group88 used synthetic peptidomimetics of tetra-
peptide Apicidin, a naturally existing inhibitor of histone deacety-
lase (HDAC), to study the inhibition potency of the molecules in
diﬀerent conformations. They synthesizedmimics of Apicidin with
triazoles mimicking diﬀerent percentage combinations of cis/trans
peptide bonds. The results showed that the peptidomimetic with
1,5-substituted triazole was bioactive, and could mimic a cis–trans–
trans–trans geometry (Fig. 4a and b), and this further supported
that this cis–trans–trans–trans geometry was the bioactive confor-
mation of Apicidin. Ghadiri’s group also synthesized and analyzed
1,4-substituted triazole-based peptidomimetics as ligands for the
somatostatin receptor (SSTR).89 In this study, the group used 1,4-
substituted 1,2,3-triazole to mimic trans-peptide bonds.
Amide bond isosteres have also been created as peptide
mimics. Based on previous developments, Wipf and coworkers
compared diﬀerent trisubstituted (E)-alkene isosteres90 (Fig. 4c).
They found that the triuoromethylated derivative was the best
combination of both the stereo eﬀect with the electrostatic
eﬀect when mimicking the amide bond. Recently, an oxetanyl-
amine fragment with non-hydrolysable property and a similar
H-bond pattern was used to replace the amide bond (Fig. 4d).
With the introduction of this structural fragment, oxetanyl
peptides91 were developed as a novel peptidomimetic for
potential pharmaceutical applications.3. Non-natural poly-amide based
secondary structure mimics to
modulate protein–protein interactions
Considering that native proteins are all made up of 20 natural a-
amino acids, several mimics starting from the non-naturalRSC Adv., 2016, 6, 61599–61609 | 61601
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View Article Onlineamino acid monomer level have been developed. These non-
natural units include b-amino acids, g-amino acids, peptoids,
etc. These polymers or oligomers with denite secondary
structures are also referred to as foldamers.92 Herein, b-peptide
and peptoid will be discussed due to their wide popularity. The
reader is directed to previous reviews for discussion of g-
peptide,93,94 d-peptide,95 3-peptide,96 or peptides made from
cyclic amino acids (z-x-peptides),97,98 or oligomers of diamine
and dicarboxylic acid known as “retro-inverso peptides”.99,100
3.1 b-Peptide & its analogs
b-Amino acids are similar to a-amino acids in that they contain
an N-terminus amino group and a C-terminus carboxyl group.
b-Peptides are composed of b-amino acids which can exist as R
or S isomers at either the a-carbon (C2) or the b-carbon (C3).
The vast range of stereo- and regioisomers signicantly expand
the structural diversity of b-peptides (Fig. 5a). The introduction
of b-amino acids has been achieved for the synthesis of b-
peptides that not only have potent activity to modulate protein–
protein interactions, but are also stable against proteolytic
degradation. The applications of bioactive b-peptides include as
receptor agonists, antimicrobial peptides, peptidase inhibitors
and so on.
In their pioneering work, Seebach and coworkers101 synthe-
sized a series of small b-peptides (Fig. 5b), and a 2D-NMR
structural study showed that these a-peptide mimics could
form a rather stable 314-helix structure. In these patterns, each
amino group from the ith residue can hydrogen bond with the
corresponding carboxyl groups from the (i + 2)th residue.
Therefore, each helical cycle contains exactly three b-amino acid
units. Gellman’s group102 extended these structures from linear
b-amino acids to cyclo-b-amino acids. The incorporation of the
two main chain carbon atoms into a certain alkyl-ring can
increase the rigidity of the substrates. They rst evaluated theFig. 5 Diﬀerent types of b-peptide and its analogs. (a) Linear b-
peptides with diﬀerent possible side chain substitution groups, (b) an
example of a b2-peptide (ref. 92), (c) oligomers of trans-2-amino-
cyclohexanecarboxylic acid (trans-ACHC) as a cyclic b-peptide, (d)
poly-(a-aminoxy acids) as a b-peptide analog, (e) oligomer b-sulﬁna-
mides (n ¼ 1) or b-sulfonamides (n ¼ 2).
61602 | RSC Adv., 2016, 6, 61599–61609molecular energies with the existence of diﬀerent numbered
rings via computational methods, and the conguration rela-
tionships on the rings were also considered. Then, several
related oligomers with trans-2-aminocyclohexanecarboxylic acid
(trans-ACHC) (Fig. 5c) were synthesized and NMR data showed
that they adopt a highly stable helix structure.103
Considering the structural similarity, poly-(a-aminoxy acids)
as a b-peptide analog was developed by replacing one of the
carbon atoms with an oxygen atom (Fig. 5d).104,105 Yang and
coworkers rst synthesized the scaﬀolds, which exhibited an
unexpected i to i + 2 hydrogen bond model to form an eight
membered ring.106 This novel turn and helix structure geometry
has not been observed for a normal b-peptide. Another thing
worth mentioning is that the hybrids of these monomers could
form completely diﬀerent structures. Kunwar’s group107
designed and synthesized a hybrid of b-amino acids and a-
aminoxy acids, which produced a 12/10-helix as a novel folding
motif. Currently, poly-(a-aminoxy acids) has been applied as
a chloride receptor to facilitate chloride anion transport across
articial liposomes, which may benet the transportation in
living cell membranes.108
Additionally, some other b-peptide derivatives have also
been introduced for the purpose of a-peptide secondary struc-
ture mimicking, with a large structural diversity.109 Sulnamide
and sulfonamide derivatives, for example, serve as the analogs
of carboxamide intermediates due to the coordination numbers
of sulphur atoms of three or four, as well as the potentially
similar hydrogen-bonding model. Sulnamides or sulfon-
amides can work as carboxyl group analogs especially when
forming intermediates in typical nucleophilic addition reac-
tions. b-Sulnamide or b-sulfonamide oligomers are introduced
as carboxylic peptide structural mimics, which signicantly
extended the structural diversity and exibility of normal
carbon based b-peptides (Fig. 5e).110 These types of oligomers
were prepared using the solid phase synthesis method111 and
employed as potential inhibitors of HIV protease.112
One outstanding feature of b-peptide is its helix formation
manner, which is similar to that of a-peptides. Although normal
b-peptides have a 314 helical conformation through the [(i)
NH/O]C (i + 2)] H-bond (Fig. 6a), diﬀerent substitution
models might result in diﬀerent H-bonding structures even
inside a single b-peptide. For example, 12/10/12 is a term used
to describe a group of b-peptides in which the H bonding
models at both terminal residues are diﬀerent from those in the
middle (Fig. 6b shows the ring containing either 12 or 10
atoms). In contrast, g-peptides (discussed in Part 3.2) are nor-
mally in a 2.614 helix conformation (Fig. 6c).
Turn structures can also be mimicked in b-peptides by the
introduction of a non-amino acid unit into a b-peptide
sequence. The Gellman group made a nucleating turn mimic in
b-peptides.113 They utilized a heterochiral nipecotic acid dimer
turn to promote a hairpin structure in adjoining b-peptide
strands. Seebach and coworkers took another approach to make
turns in b-peptides.114 They utilized a b-dipeptide from the
central ten-membered hydrogen-bonded turn of the 12/10/12
helix, and showed that b-peptides inserted with these two
homochiral b-amino acids took on a similar conformation toThis journal is © The Royal Society of Chemistry 2016
Fig. 6 Helix structures for b-peptides and g-peptide. (a) Normal b-
peptide helical plot, (b) special 12/10/12 helical plot, (c) g-peptide
helical plot.
Review RSC Advances
Pu
bl
ish
ed
 o
n 
15
 Ju
ne
 2
01
6.
 D
ow
nl
oa
de
d 
by
 C
al
ifo
rn
ia
 In
sti
tu
te
 o
f T
ec
hn
ol
og
y 
on
 2
9/
07
/2
01
6 
18
:4
7:
01
. 
View Article Onlinethat in the turn of that 12/10/12 helix. The structural design,
followed by characterization, are still the main tasks of b-
peptide studies. However, rational design combined with
computational prediction remains challenging for the purpose
of helix mimicking, with limited achievements so far.
b-Peptides have been applied in several diﬀerent medical
elds. The Seebach group made use of a b-peptide with a 14-
helix structure for inhibition of the apolipoprotein–receptor
interaction.115 Tests of antibacterial activity showed that some b-
peptides even had micromolar IC50 values as well as high cell
lysis activity. For example, three diﬀerent b-peptides have been
developed as potential inhibitors of cholesteryl oleate uptake,
which could successfully fold into 314-helices to exhibit an
amphipathic character (Fig. 7a–c) with a range of IC50 values.
On the other hand, these peptides with high cytotoxicity showed
similar eﬀects on both red blood cells and bacterial cells. To
summarize, b-peptides with carefully optimized lengths and
structures may be candidates for novel antibiotics.1163.2 Peptoids
Peptoids are a class of articial peptidomimetics with the side
chains covalently linked to the nitrogen atom, rather than to theFig. 7 Structural examples of b-peptides serving as cholesteryl oleate
uptake inhibitors. (a–c) Three examples of b-peptides with diﬀerent
side chain substitution groups (ref. 115).
This journal is © The Royal Society of Chemistry 2016a-carbons.117 b-Peptoids (N-alkyl-b-alanines), with the N-substi-
tution of b-peptides, have been reported as another type of
backbone-modied peptide mimics (Fig. 8a and b),118 which
also have applications in drug or gene delivery.119
Unlike natural peptides, no hydrogen bond donor exists in
the backbone of peptoids, and the major forces which stabilize
the secondary structures of peptoids are steric and electronic
interactions.120 X-ray crystal structure analysis shows that this
special group of peptoids can exhibit a similar structure to
polyproline I peptide helix121 (Fig. 8c). Furthermore, Shin et al.
reported peptoid macrocycles forming a reverse-turn
conformation.122
Desired peptoids can be produced via solid phase synthesis
with high convenience, low cost, and high eﬃciency. Addi-
tionally, any primary amine can be incorporated into a peptoid
using a submonomer synthetic method. Therefore, we can
extend the choice of side chains from natural amino acid side
chains to theoretically any desired articial group.123 The rst
preparation of peptoids by solid-phase synthesis was proposed
by Zuckermann et al. in 1992.124 More recently, other methods
for the solid phase synthesis of a-peptoids and their derivatives
have been developed.125 Typical strategies of polymer synthesis,
such as living alternating copolymerization between carbon
monoxide and N-alkylaziridines, can also be applied to peptoid
synthesis.126 There are also established methods for the
synthesis of b-peptoids.127
Because of their versatile natural properties and well-
established synthetic methodologies, peptoids have been
widely applied in drug design and fundamental biological
research. Moreover, peptoids are resistant to proteolysis, which
is a critical advantage over natural peptides for therapeutic
applications. One of the earliest and most obvious applications
of peptoids is to screen the binding partners of target proteins
(especially receptors). Scientists at Chiron Corporation 127 rst
demonstrated this application by screening a combinatorial
library of peptoids for ligands of the famous G-protein coupled
receptors (GPCRs), which were well known as targets of many
drugs. They synthesized a library of dimer or trimer peptoids
with diﬀerent substitution groups (Fig. 9a). Then, they screened
the library in competitive radioligand-binding assays resulting
in the discovery of some high-aﬃnity ligands for GPCR. Several
peptoids were selected for the a-adrenergic acceptor (Fig. 9b)Fig. 8 Structure of a-peptoid and b-peptoid compared with normal
peptide. (a) a-Peptoid (b) b-peptoid (c) N-(1-cyclohexylethyl)glycine
oligomer as an example of b-peptoid (ref. 112).
RSC Adv., 2016, 6, 61599–61609 | 61603
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View Article Onlineand for the m-specic opiate receptor (Fig. 9c) with binding
constants of 5 nM and 6 nM, respectively. Kodadek’s group129
carried out a series of studies in an attempt to apply a similar
strategy to screen for ligands for vascular endothelial growth
factor receptor 2 (VEGFR2) with a cell-based, double-colored
assay. Among the VEGFR2-binding peptoids, they found
a candidate as a decent antagonist of VEGFR2 activity with a KD
value of around 20 nM. In another study, the same group130 used
a similar approach to identify antibodies that could be useful
for diagnosis of diseases, and surprisingly they found two
antibody IgGs as biomarker candidates for Alzheimer’s disease.
Additionally, Barron and coworkers used peptoids as synthetic
lung surfactants or novel antimicrobial agents. They developed
the novel concept of “ampetoids” (antimicrobial peptoid olig-
omers), and demonstrated that the ampetoids could have an
analogous mechanism to those of AMPs in vitro.131 In addition,
they also exploited peptoids as good mimics of SP-C, a key part
of the pulmonary surfactant system.132
In spite of the progresses described above, it still remains
challenging to design peptoids to mimic desired peptide
structures, because of the diﬃculties in predicting the structure
of the peptoids. Peptoids lack the regular hydrogen bonding
that exists in natural protein secondary structures.133 Therefore,
additional forces (such as steric or electronic interactions) are
usually introduced into the peptoids to form secondary struc-
ture mimics, which makes the calculation of energies associ-
ated with diﬀerent conformations particularly diﬃcult.1344. Non-amide polymer based
secondary structure mimics to
modulate protein–protein interactions
It is much more challenging to make up protein-like scaﬀolds
from non-amide oligomers/polymers. However, this group of
mimics turned out to exhibit more tailorable structures, some
of which have been successfully applied to bind with certain
biomacromolecules. The key point is to introduce an element of
asymmetry into the non-amide oligomers and to make them
exhibit the expected structures. Only under these conditions
can the articial scaﬀolds locate their substituents in a similar
orientation to the native peptide secondary structures.
The rst class of non-amide oligomers has an asymmetric
centre axis to mimic the overall backbones in a a-helixFig. 9 Peptoids as peptide mimics for the purpose of PPI: (a) general
structure of a-peptoid; (b) and (c) structural examples of peptoids
serving as GPCR binders with nanomolar binding constants.
61604 | RSC Adv., 2016, 6, 61599–61609structure, guided by information on the protein structure–
activity relationship. The substituent groups are arranged in
a rotating manner, as analogs to amino acid residues, which
originates from steric eﬀects (Fig. 10).4.1 Oligophenyl scaﬀold and its derivatives
Oligophenyl scaﬀold and its derivatives are the rst class of
molecules with structural interest.135 The sequential aromatic
rings linked by a single bond are not in the same molecular
plane, giving the essential element of asymmetry.136 Hamilton
et al.137 rst made use of the rigid framework resulting from o-
substituted terphenyl as an a-helix mimic (Fig. 11a). In these
structures, the distance between two substituent groups local-
ized on two adjacent phenyl groups is 5–6 A˚, whichmimics the i,
i + 4, and i + 7 side chains along a helix. This class of peptido-
mimetics has been the most successful in the search for PPI
inhibitors or antagonists. Bcl-xL is an anti-apoptotic protein
overexpressed in some cancer cell lines, which protects the
tumour cells from dying even under apoptotic signal condi-
tions. The following two examples dealt with this protein.
Hamilton’s group developed several terphenyl derivatives to
mimic the a-helix of Bak-protein to bind with Bcl-xL, acting as
potential Bcl-xL antagonists.138 NMR data showed an expected
binding model with a binding constant KD in the range of mM to
nM, in agreement with the predicted docking result. Aer that
work, the same group further established a terphenyl derivative
library based on the mimicking of the a-helix Bak-protein BH3
domain.139 In vivo experiments in the embryonic kidney 293T
cell line showed the interruption of the binding between two
protein moieties in the presence of certain secondary structural
mimics. The same design principle has also been applied to
study inhibitors for the p53/HDM2 interaction, the inhibition of
which is of great importance for anticancer therapy. Hamilton
and coworkers further established a terphenyl candidate library
via multiple Suzuki coupling reactions. Through substitution
group screening, terphenyl derivatives were found that
mimicked the peptide 15–31 of p53 folding as an a-helix. The
NMR mapping results showed similar interaction modes to
those of the native peptide at the binding pockets of F19 (i), W23
(i + 4), and L26 (i + 7) on HDM2, with high aﬃnities.140
An enaminone structure was incorporated into the benzene
backbone to overcome the diﬃculty in synthesis as well as its
low water solubility (Fig. 11b and c). Because of the specialFig. 10 Scheme for the design principle for a straight stick scaﬀold
with rotating arranged twigs as a helix mimic.
This journal is © The Royal Society of Chemistry 2016
Fig. 11 Oligophenyl scaﬀold and its derivatives as helix mimics. (a–f)
Oligophenyl scaﬀold and its derivatives, aiming to show the possible
usages of diverse aromatic ring structures.
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View Article Onlineintramolecular hydrogen bonding models, these compounds141
are still shown to have the capacity to mimic the i, i + 4, and i + 7
side chains along a helix. Through substituent group optimi-
zation, these structures142 can also bind successfully to the
hydrophobic pocket of Bcl-xL with a similar pattern to Bak-
protein. Another alternative design comes from the replace-
ment of the benzene ring with other heteroatom-containing
rings, including imidazole, thiazole, oxazole, and piperazine
(Fig. 11d and e).
In 2007, Hamilton and coworkers made some improvements
to the design principle. Through the sophisticated calculation
of the relative positions in space, they veried that a 2,6,30-
trisubstituted biaryl scaﬀold would mimic not only i and i + 4
but also i + 3 position at the same time (Fig. 11f).143 Aer
a careful optimization of substituent groups, the newly gener-
ated structures could bind to the ligand-binding domain of the
estrogen receptor to inhibit the protein receptor interacting
with its native ligand, and thus regulate downstream eﬀects.Fig. 12 (a) An example of oligobenzamide scaﬀold (ref. 128), (b–d)
diﬀerent oligobenzamide scaﬀold derivatives as helix mimics (ref. 140).
(e) An example of polycyclic ether (ref. 137).
This journal is © The Royal Society of Chemistry 2016One disadvantage of this mimic group is its poor water solu-
bility, which can be improved using the oligobenzamide family.
Peptide–nucleic acid interactions (PNIs) are another group of
important inter-macromolecular interactions, having similar
properties and models to PPIs. Therefore, terphenylene deriv-
atives,134 as peptide secondary structure mimics, can also be
applied to regulate PNIs.4.2 Oligobenzamide scaﬀold and its derivatives
Another sub-category of compounds based on non-amide olig-
omers is compounds with diﬀerent linkages between the
aromatic rings, from a single and rotatable bond to some more
complicated spacers.144 Besides the oligo-p-amino picolinic acid
(Fig. 12a), the most widely used groups of molecular units are
trisbenzamide derivatives (Fig. 12b–d). Three alkoxyl substitu-
tion groups can also be used to mimic the i, i + 4, and i + 7 side
chains of a native helix structure. The synthesis and charac-
terization of these small molecules have been studied,145 and
some of them have been applied to protein–protein interaction
inhibition. The distances between the oligomer units are not
absolutely the same compared with each pitch of the screw in
native a-helical structures. It is worth considering that the
accumulation of error in the overall shape might be a problem
in the mimicking of longer helixes. The incorporation of oxygen
atoms can also increase the aqueous solubility of compounds
from this group.146
Based on similar design principles, Oguri and collabora-
tors147 designed and synthesized a polycyclic ether as the
backbone scaﬀold (Fig. 12e). These foldamers, inspired by
polycyclic ether marine toxins, can mimic the position of i, i + 3,
i + 4, i + 7, and i + 8. Novel peptidomimetics with structures
belonging to this group are continually being developed, such
as oligooxopiperazine based on computer-aided rational
design, targeting diverse PPIs.148,149 These mimics may also be
candidates for the inhibition of protein–protein interactions. By
introducing chemical handles onto these scaﬀolds, bio-
orthogonal reactions can be applied for the purposes of modi-
cation or functionalization, which may further modulate the
inhibition eﬀects.150 Using this design, Wilson and co-
workers151 further developed a cross-linked dimer strategy as
a “multivalent mimic of helix” with increased aﬃnity, by using
intermolecular click reactions on the handles.5. Conclusion and outlook
The study of protein–protein interactions has become an
important topic due to their key roles in cellular processes and
the eﬃcacy of molecules as drugs. An increasing number of
chemical strategies have been developed to create protein/
peptide secondary structural mimics that target specic
protein–protein interactions.152 The versatile, robust, and easily
controllable chemical structures and the ne tuning of physical
properties endow these peptidomimetics with the potential for
high binding aﬃnity and specicity.153 In this review, we
divided the existing peptide mimics into three major groups
based on their structural diversities, and briey discussed theirRSC Adv., 2016, 6, 61599–61609 | 61605
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View Article Onlinedesign, synthesis and their applications in the modulation of
PPIs.
One of the biggest goals faced in the eld is to create more
peptide secondary mimics with diverse novel chemical struc-
tures.154 All categories of current peptide mimics are based on
repeating structure units, which can exhibit a rotation structure
to mimic helices.155 The possibilities of structural design for the
purpose of mimicking are theoretically unlimited, and thus
molecular designs could number far more than those discussed
above.156 Interestingly, small molecules can also serve as helix
mimics, such as the 2,6,9-tri-substituted purine introduced by
Fletcher et al.157 At the same time, the combination of physical
chemistry analysis and chemical design can predict better
mimetic structures.158 If we think out of the box, these helices
can be regarded as incomplete and unstable barrels with hollow
chambers. Thus, non-repeating molecules may also be able to
play a scaﬀold role as an entire barrel.159 Besides attempts to
mimic a-helices, b-strand/sheets and turns, loops are also an
important but challenging task, which has not been fully
emphasized.
Another important goal is to make use of peptidomimetics
for screening and to search for leads for medical applications.160
Advances have been made towards the design and synthesis of
diverse oligomer foldamers for those purposes,161 as well as
building mimic libraries for targeting PPIs.162 Compared with
the traditional screening processes of small molecular or
peptide inhibitors,163 some basic facilities still need to be fully
established for both rational design and high-throughput
screening of peptidomimetics.164 We expect that more and
more peptide mimics based on rational design may be applied
as new chemical tools and potential clinical therapeutics in the
near future.165
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